PubMed Journals Articles About "Anthera Halts VISTA Heart Drug Trial" 
Anthera Halts VISTA Heart Drug Trial PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Anthera Halts VISTA Heart Drug Trial articles that have been published worldwide.
More Information about "Anthera Halts VISTA Heart Drug Trial" on BioPortfolio
We have published hundreds of Anthera Halts VISTA Heart Drug Trial news stories on BioPortfolio along with dozens of Anthera Halts VISTA Heart Drug Trial Clinical Trials and PubMed Articles about Anthera Halts VISTA Heart Drug Trial for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Anthera Halts VISTA Heart Drug Trial Companies in our database. You can also find out about relevant Anthera Halts VISTA Heart Drug Trial Drugs and Medications on this site too.
Showing "Anthera halts VISTA heart drug trial" PubMed Articles 1–25 of 42,000+
BACKGROUND: Patients undergoing carotid endarterectomy for extracranial internal carotid artery stenosis are at risk of cerebral ischemia/hypoperfusion. Criterion recommended by European and American committees to determine whether to place a shunt consisted of a decline in transcranial Doppler ultrasonography-measured middle cerebral artery blood flow velocity (MCBFV) to < 30% to 40% of intraoperative preclamp value. OBJECTIVE: To assess the discriminative power of the bispectral index (BIS)-Vista monitor...
Clinical Trial Report: Treatment of Nonalcoholic Steatohepatitis with Vitamin E.
Cancer research. As questions grow, Duke halts trials, launches investigation.
This study sought to examine the association between baseline beta-blocker (BB) dose and outcomes in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.
Effects of orthoses on three-dimensional load-displacement properties of the cervical spine.
PURPOSE: Our objectives were to develop a skull-neck-thorax model capable of quantifying spinal motions in an intact human cadaver neck with and without cervical orthoses, determine the effect of orthoses on three-dimensional load-displacement properties of all cervical spinal levels, and compare and contrast our results with previously reported in vivo data. METHODS: Load input flexibility tests were performed to evaluate two cervical collars (Vista(®) collar and Vista(®) Multipost collar) and two cervic...
OBJECTIVES: The objective was to test the hypothesis that heart failure (HF) patients treated with sertraline will have lower depression scores and fewer cardiovascular events compared with placebo. BACKGROUND: Depression is common among HF patients. It is associated with increased hospitalization and mortality. METHODS: The SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial was a randomized, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day vers...
Trial watch: Genetic association studies link interleukin-6 receptor to coronary heart disease.
The study investigated whether the number of participants enrolled per site in an acute heart failure trial is associated with participant characteristics and outcomes.
BACKGROUND: Raised resting heart rate is a marker of cardiovascular risk. We postulated that heart rate is also a risk factor for cardiovascular events in heart failure. In the SHIFT trial, patients with chronic heart failure were treated with the selective heart-rate-lowering agent ivabradine. We aimed to test our hypothesis by investigating the association between heart rate and events in this patient population. METHODS: We analysed cardiovascular outcomes in the placebo (n=3264) and ivabradine groups (n...
We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES).
Judge halts US funding of embryonic stem cell research.
The Edwards SAPIEN transcatheter heart valve (THV) is approved for aortic stenosis patients considered inoperable because of high surgical risk. Based on the high-risk arm of the PARTNER trial, the Food and Drug Administration's Circulatory System Devices Panel reviewed an additional indication for use in high-risk, operable patients. Although several concerns were raised regarding safety, trial misconduct, and several subgroup analyses, most panel members agreed that the Edwards SAPIEN THV (Edwards Lifesci...
Failures of cobalamin assays in pernicious anemia.
Failures of Cobalamin Assays in Pernicious Anemia Correspondence, N Engl J Med 2012;367:385-386. In the final paragraph (page 386), the first sentence should have read, "The diagnostic failures with all three CBLAs suggest widespread CBLA malfunction; indeed, case reports also showed errors in the Immulite 2000 and Siemens Dimension Vista CBLAs (see the Table in the Supplementary Appendix)," rather than ". . . indeed, case reports showed errors in the Immulite 2000, Abbott Architect, and Siemens Dimension...
Statins in Combinations: From ARBITER-6 HALTS to ACCORD-What Works?
BACKGROUND: Previous studies suggested that transplantation of autologous bone marrow-derived mononuclear cells (BMNCs) improves heart function in chronic chagasic cardiomyopathy. We report the results of the first randomized trial of BMNC therapy in chronic chagasic cardiomyopathy. METHODS AND RESULTS: Patients 18 to 75 years of age with chronic chagasic cardiomyopathy, New York Heart Association class II to IV heart failure, left ventricular ejection fraction (LVEF)
We determined the outcome of cardiac allografts from multiorgan donors enrolled in a randomized trial of donor pre-treatment with dopamine.
BACKGROUND: The action of secretory phospholipase A(2) (sPLA(2)) on lipoproteins may render them more susceptible to oxidation, thereby promoting vascular inflammation and increasing cardiovascular risk. Patients with acute coronary syndrome face a high risk of early, recurrent cardiovascular events that is associated with biomarkers of inflammation, including sPLA(2). The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246) tests the...
Trial watch: Apixaban beats warfarin in stroke trial.
Trial watch: Sepsis study failure highlights need for trial design rethink.
Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial.
Diastolic heart failure (ie, heart failure with preserved ejection fraction) is a common condition without established therapy, and aldosterone stimulation may contribute to its progression.
BACKGROUND: -Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. Methods and Results-The circulating concentration of GDF-15 was measured at baseline (n=1734) and at 12 months (n=1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high (>1200 ng/L) in 85% of pati...
ABSTRACT: BACKGROUND: Current guidelines recommend dual anti-platelet therapy, aspirin and clopidogrel, for patients treated with drug-eluting stent for coronary heart disease. In a few small trials, addition of cilostazol on dual anti-platelet therapy (triple anti-platelet therapy) showed better late luminal loss. In the real-world unselected patients with coronary heart disease, however, the effect of cilostazol on platelet reactivity and ischemic vascular events after drug-eluting stent implantation has...
Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly.
Guideline-recommended beta-blocker (BB) target doses for patients with chronic heart failure can often not be reached. This secondary analysis of the CIBIS-ELD trial was carried out to better understand reasons for not achieving target doses.
Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used β-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, resp...
